Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Rich

Showing results (371-380 of 558) with videos related to

Pageof 56
Sort By:
Cancer Discovery|April 7, 2026
Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for GlioblastomaNianxin Zhou, Fan Fei, Lin Tang, et al.
Cancer Research|December 14, 2021
Leveraging Allele-Specific Expression for Therapeutic Response Gene Discovery in GlioblastomaArko Sen, Briana C Prager, Cuiqing Zhong, et al.
Cancer|February 29, 2012
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade gliomaDavid A Reardon, Annick Desjardins, James J Vredenburgh, et al.
Cell|April 2, 2013
Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growthLin Cheng, Zhi Huang, Wenchao Zhou, et al.
Cancer Research|February 28, 2016
Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical ModelsJosephine Kam Tai Dermawan, Masahiro Hitomi, Daniel J Silver, et al.
Nature Biomedical Engineering|December 11, 2024
Publisher Correction: Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein bindersZhen Xia, Qihan Jin, Zhilin Long, et al.
Genes & Development|June 5, 2012
Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneityYoungmi Kim, Eunhee Kim, Qiulian Wu, et al.
Neuro-Oncology|August 19, 2010
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant gliomaSith Sathornsumetee, Annick Desjardins, James J Vredenburgh, et al.
The Journal of Biological Chemistry|July 14, 2009
NDRG4 is required for cell cycle progression and survival in glioblastoma cellsStephen H Schilling, Anita B Hjelmeland, Daniel R Radiloff, et al.
Cell Death and Differentiation|May 17, 2014
Phage display discovery of novel molecular targets in glioblastoma-initiating cellsJ K Liu, D Lubelski, D L Schonberg, et al.
Pageof 56

Showing results (371-380 of 558) with videos related to

Sort By:
Pageof 56
Cancer Discovery|April 7, 2026
Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for GlioblastomaNianxin Zhou, Fan Fei, Lin Tang, et al.
Cancer Research|December 14, 2021
Leveraging Allele-Specific Expression for Therapeutic Response Gene Discovery in GlioblastomaArko Sen, Briana C Prager, Cuiqing Zhong, et al.
Cancer|February 29, 2012
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade gliomaDavid A Reardon, Annick Desjardins, James J Vredenburgh, et al.
Cell|April 2, 2013
Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growthLin Cheng, Zhi Huang, Wenchao Zhou, et al.
Cancer Research|February 28, 2016
Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical ModelsJosephine Kam Tai Dermawan, Masahiro Hitomi, Daniel J Silver, et al.
Nature Biomedical Engineering|December 11, 2024
Publisher Correction: Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein bindersZhen Xia, Qihan Jin, Zhilin Long, et al.
Genes & Development|June 5, 2012
Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneityYoungmi Kim, Eunhee Kim, Qiulian Wu, et al.
Neuro-Oncology|August 19, 2010
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant gliomaSith Sathornsumetee, Annick Desjardins, James J Vredenburgh, et al.
The Journal of Biological Chemistry|July 14, 2009
NDRG4 is required for cell cycle progression and survival in glioblastoma cellsStephen H Schilling, Anita B Hjelmeland, Daniel R Radiloff, et al.
Cell Death and Differentiation|May 17, 2014
Phage display discovery of novel molecular targets in glioblastoma-initiating cellsJ K Liu, D Lubelski, D L Schonberg, et al.
Pageof 56